Stock listing
Hanover:ZEG AstraZeneca PLC Aktie
German listing (Hanover) of AstraZeneca PLC · home listing LSE:AZN
Follow AstraZeneca PLC into a list and get an email when it puts out news.
Home listing price · LSE:AZN
13,412p GBX (pence) -234 (-1.7%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, LSE:AZN
- Day range
- 13,350p – 13,538p GBX (pence)Nov 20, 2026
- Volume
- 2.18M sharesNov 20, 2026
- Market cap
- £208.0B GBPAt the close on Nov 20, 2026 · price × 1.55B shares outstanding
- 52-week range
- 9,892.00p – 15,732p GBX (pence)Lowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- £342.8M GBPMedian day 2.26M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| LSE:AZN · Home | 13,412p GBX (pence) | -234 (-1.7%) | 2,180,343 | 13,432p | 13,538p | 13,350p | 13,646p | Close on Nov 20, 2026 |
| NYSE:AZN | $174.35 USD | -1.06 (-0.6%) | 2,022,735 | $176.14 | $177.47 | $174.04 | $175.41 | Close on Nov 20, 2026 |
| Stockholm:AZN | 1,796.00 SEK | +18.50 (+1.0%) | 462,554 | 1,790.00 | 1,812.00 | 1,784.50 | 1,777.50 | Close on Nov 20, 2026 |
| Frankfurt:ZEG | €159.55 EUR | -2.15 (-1.3%) | — | €159.60 | €161.50 | €159.20 | €161.70 | Close on Nov 20, 2026 |
| B3:A1ZN34 | 174.09 BRL | -1.91 (-1.1%) | 179 | 173.57 | 174.09 | 172.28 | 176.00 | Close on Nov 19, 2026 |
| Stuttgart:ZEG | €158.95 EUR | -0.75 (-0.5%) | 56 | €158.35 | €161.05 | €158.35 | €159.70 | Close on Nov 20, 2026 |
| Munich:ZEG | €158.35 EUR | -0.95 (-0.6%) | — | €158.90 | €158.90 | €158.35 | €159.30 | Close on Nov 20, 2026 |
| Hamburg:ZEG | €160.10 EUR | +1.60 (+1.0%) | — | €158.45 | €160.10 | €158.40 | €158.50 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · LSE:AZN · GBX (pence), adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 13,412p | -234 | -1.7% | 13,432p | 13,538p | 13,350p | 2,180,343 | |
| 13,646p | -156 | -1.1% | 13,770p | 13,850p | 13,578p | 1,591,835 | |
| 13,802p | -232 | -1.7% | 13,938p | 13,956p | 13,722p | 1,619,308 | |
| 14,034p | +52 | +0.4% | 14,056p | 14,222p | 13,964p | 2,286,583 | |
| 13,982p | +52 | +0.4% | 13,902p | 14,064p | 13,892p | 1,059,168 | |
| 13,930p | +34 | +0.2% | 14,024p | 14,080p | 13,890p | 2,096,019 | |
| 13,896p | +12 | +0.1% | 13,902p | 13,962p | 13,824p | 1,328,928 | |
| 13,884p | -182 | -1.3% | 14,114p | 14,148p | 13,884p | 3,288,630 | |
| 14,066p | +136 | +1.0% | 13,920p | 14,184p | 13,918p | 1,520,835 | |
| 13,930p | -112 | -0.8% | 13,696p | 13,950p | 13,458p | 2,588,516 | |
| 14,042p | +18 | +0.1% | 14,228p | 14,312p | 13,966p | 5,685,723 | |
| 14,024p | +264 | +1.9% | 13,768p | 14,062p | 13,582p | 3,691,327 | |
| 13,760p | -100 | -0.7% | 13,964p | 13,984p | 13,760p | 2,262,803 | |
| 13,860p | -100 | -0.7% | 13,704p | 13,932p | 13,678p | 2,535,557 | |
| 13,960p | +908 | +7.0% | 13,438p | 14,002p | 13,308p | 4,546,444 | |
| 13,052p | +288 | +2.3% | 12,808p | 13,166p | 12,782p | 1,401,291 | |
| 12,764p | -58 | -0.5% | 12,756p | 12,932p | 12,642p | 1,158,441 | |
| 12,822p | -32 | -0.2% | 12,848p | 12,912p | 12,724p | 2,178,329 | |
| 12,854p | +30 | +0.2% | 12,882p | 12,976p | 12,806p | 1,603,348 | |
| 12,824p | -156 | -1.2% | 12,906p | 12,906p | 12,672p | 2,108,440 | |
| 12,980p | +366 | +2.9% | 12,602p | 12,980p | 12,520p | 1,798,652 | |
| 12,614p | -4 | 0.0% | 12,602p | 12,692p | 12,536p | 1,768,801 | |
| 12,618p | +218 | +1.8% | 12,440p | 12,626p | 12,386p | 4,422,284 | |
| 12,400p | -46 | -0.4% | 12,440p | 12,470p | 12,298p | 2,088,289 | |
| 12,446p | -252 | -2.0% | 12,506p | 12,576p | 12,418p | 2,901,078 | |
| 12,698p | +398 | +3.2% | 12,396p | 12,806p | 12,334p | 5,442,067 | |
| 12,300p | +404 | +3.4% | 11,820p | 12,330p | 11,816p | 2,182,102 | |
| 11,896p | -130 | -1.1% | 12,170p | 12,310p | 11,882p | 2,152,484 | |
| 12,026p | +28 | +0.2% | 12,038p | 12,078p | 11,916p | 1,751,377 | |
| 11,998p | +106 | +0.9% | 12,024p | 12,112p | 11,982p | 4,458,670 | |
| 11,892p | -288 | -2.4% | 12,032p | 12,124p | 11,890p | 2,276,972 | |
| 12,180p | +222 | +1.9% | 11,912p | 12,180p | 11,894p | 1,721,628 | |
| 11,958p | +194 | +1.6% | 11,904p | 12,112p | 11,782p | 2,189,050 | |
| 11,764p | -106 | -0.9% | 11,900p | 11,972p | 11,716p | 1,619,066 | |
| 11,870p | -162 | -1.3% | 11,800p | 12,094p | 11,790p | 1,659,275 | |
| 12,032p | -248 | -2.0% | 12,014p | 12,281p | 12,010p | 3,717,062 | |
| 12,280p | -148 | -1.2% | 12,436p | 12,518p | 12,250p | 3,855,859 | |
| 12,428p | -64 | -0.5% | 12,526p | 12,788p | 12,386p | 2,735,445 | |
| 12,492p | -60 | -0.5% | 12,614p | 12,632p | 12,446p | 1,550,979 | |
| 12,552p | +152 | +1.2% | 12,400p | 12,614p | 12,398p | 1,735,781 | |
| 12,400p | -30 | -0.2% | 12,418p | 12,506p | 12,316p | 2,112,194 | |
| 12,430p | -242 | -1.9% | 12,564p | 12,662p | 12,430p | 1,690,605 | |
| 12,672p | +112 | +0.9% | 12,606p | 12,690p | 12,478p | 4,821,834 | |
| 12,560p | +60 | +0.5% | 12,450p | 12,631p | 12,364p | 3,916,913 | |
| 12,500p | +72 | +0.6% | 12,460p | 12,596p | 12,396p | 6,543,165 | |
| 12,428p | +292 | +2.4% | 12,202p | 12,428p | 12,148p | 2,815,365 | |
| 12,136p | +20 | +0.2% | 12,098p | 12,296p | 12,074p | 5,327,145 | |
| 12,116p | -38 | -0.3% | 12,236p | 12,236p | 11,922p | 3,056,945 | |
| 12,154p | +446 | +3.8% | 11,698p | 12,218p | 11,692p | 6,470,194 | |
| 11,708p | -50 | -0.4% | 11,810p | 11,960p | 11,708p | 1,474,760 | |
| 11,758p | +108 | +0.9% | 11,634p | 11,802p | 11,552p | 2,070,437 | |
| 11,650p | -226 | -1.9% | 11,850p | 11,998p | 11,598p | 3,566,251 | |
| 11,876p | -166 | -1.4% | 11,958p | 12,122p | 11,852p | 2,302,552 | |
| 12,042p | +36 | +0.3% | 11,986p | 12,210p | 11,952p | 1,976,565 | |
| 12,006p | -140 | -1.2% | 12,146p | 12,210p | 11,984p | 2,248,699 | |
| 12,146p | +170 | +1.4% | 12,066p | 12,290p | 12,018p | 2,394,368 | |
| 11,976p | +14 | +0.1% | 12,032p | 12,194p | 11,846p | 2,766,204 | |
| 11,962p | -8 | -0.1% | 11,650p | 12,132p | 11,650p | 2,914,975 | |
| 11,970p | -144 | -1.2% | 12,200p | 12,200p | 11,958p | 3,627,956 | |
| 12,114p | -120 | -1.0% | 12,194p | 12,236p | 12,066p | 3,580,853 | |
| 12,234p | -242 | -1.9% | 12,450p | 12,464p | 12,214p | 2,784,068 | |
| 12,476p | +366 | +3.0% | 12,220p | 12,476p | 12,124p | 2,036,385 | |
| 12,110p | -130 | -1.1% | 12,182p | 12,204p | 12,016p | 1,791,745 | |
| 12,240p | +152 | +1.3% | 11,926p | 12,242p | 11,926p | 2,344,334 | |
| 12,088p | +38 | +0.3% | 12,162p | 12,162p | 11,844p | 3,149,124 |
- Ticker
- Hanover:ZEG
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Hanover
- Currency
- EUR
What changed lately
Latest news release · Nov 16, 2026
Baxfendy recommended for approval in the EU
Latest earnings call · Jul 27, 2026
AstraZeneca (LSE:AZN) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Oct 30, 2026
Q3 2026 Earnings Presentation
Earnings · 153 slides
Latest news
Baxfendy recommended for approval in the EU
Nov 16, 2026
Closed 14,034p (+0.4%) on Nov 16, 2026
Imfinzi + EV approved in US in bladder cancer
Nov 16, 2026
Closed 14,034p (+0.4%) on Nov 16, 2026
Klygefa (gefurulimab) approved in the US
Nov 16, 2026
Closed 14,034p (+0.4%) on Nov 16, 2026
Klygefa (gefurulimab) approved in the EU
Nov 16, 2026
Closed 14,034p (+0.4%) on Nov 16, 2026
Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
Nov 13, 2026
Closed 14,034p (+0.4%) on Nov 16, 2026
Admission of Further Securities to Trading
Nov 2, 2026
Closed 13,860p (-0.7%) on Nov 2, 2026
Total Voting Rights
Nov 2, 2026
Closed 13,860p (-0.7%) on Nov 2, 2026
3rd Quarter Results
Oct 30, 2026
Closed 13,960p (+7.0%) on Oct 30, 2026
Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer
Oct 27, 2026
Closed 12,822p (-0.2%) on Oct 27, 2026
Enhertu approved in EU for HER2-positive eBC
Oct 27, 2026
Closed 12,822p (-0.2%) on Oct 27, 2026
AstraZeneca PLC on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 184 in the last 12 months · 871 in all · newest Nov 16, 2026 · oldest 2016
- Calls
- 16 calls with a replay · 16 with a transcript · latest Jul 27, 2026
- Decks
- 333 decks · latest Oct 30, 2026
Where AstraZeneca PLC is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| LSE:AZN · Home listing | LSE | United Kingdom | GBX |
| NYSE:AZN | NYSE | United States | USD |
| Stockholm:AZN | Stockholm | Sweden | SEK |
| gettex:ZEG | gettex | Germany | EUR |
| BCBA:AZN | BCBA | Argentina | ARS |
| Tradegate:ZEG | Tradegate | Germany | EUR |
| LS Exchange:886455 | LS Exchange | Germany | EUR |
| Frankfurt:ZEG | Frankfurt | Germany | EUR |
| B3:A1ZN34 | B3 | Brazil | BRL |
| BOATS:AZN | BOATS | United States | USD |
| Lang & Schwarz:886455 | Lang & Schwarz | Germany | EUR |
| Aquis:AZNL | Aquis | United Kingdom | GBX |
| BMV:AZNN | BMV | Mexico | MXN |
| BMV:AZN1N | BMV | Mexico | MXN |
| BCBA:AZND | BCBA | Argentina | USD |
| Turquoise:AZNL | Turquoise | United Kingdom | GBX |
| Stuttgart:ZEG | Stuttgart | Germany | EUR |
| Munich:ZEG | Munich | Germany | EUR |
| Aquis:AZNS | Aquis | United Kingdom | SEK |
| BSESOF:ZEG | BSESOF | Bulgaria | EUR |
| BCBA:AZNC | BCBA | Argentina | USD |
| BIVA:AZN1N | BIVA | Mexico | MXN |
| BX Swiss:ZEG | BX Swiss | Switzerland | CHF |
| Aquis:AZNS | Aquis | United Kingdom | SEK |
| Hamburg:ZEG | Hamburg | Germany | EUR |
| Hanover:ZEG · This page | Hanover | Germany | EUR |
| Lang & Schwarz:886715 | Lang & Schwarz | Germany | EUR |
| Turquoise:AZNS | Turquoise | United Kingdom | SEK |
| Dusseldorf:ZEG | Dusseldorf | Germany | EUR |
| LS Exchange:886715 | LS Exchange | Germany | EUR |
| BCBA:AZN.CI | BCBA | Argentina | ARS |
Valuation
P/E 24.6× against a median of 26.7×: 6th lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- £227.8B GBP
- P/E
- 24.6×
- EV/sales
- 4.8×
- EV/EBITDA
- 14.1×
- Price/book
- 5.3×
- Gross margin
- 77.6%
- Operating margin
- 23.6%
- Net margin
- 17.7%
- Debt to equity
- 0.7×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| AstraZeneca PLC · LSE:AZN | US$272.1B | US$298.0B | 24.6× | 4.8× | 14.1× | 5.3× | 17.7% | 0.7× | n/a |
| Johnson & Johnson · NYSE:JNJ | US$651.1B | US$678.5B | 40.5× | 6.8× | n/a | 8.0× | 16.2% | 0.6× | -0.02 |
| AbbVie Inc. · NYSE:ABBV | US$505.9B | US$503.8B | 48.9× | 7.6× | n/a | n/a | 15.7% | n/a | 0.00 |
| Merck & Company, Inc. · NYSE:MRK | US$329.7B | US$373.8B | 134× | 5.5× | n/a | 7.3× | 3.6% | 1.2× | 0.28 |
| Novartis AG · SIX:NOVN | US$287.4B | US$304.7B | 20.6× | n/a | n/a | 6.2× | n/a | 0.6× | n/a |
| Pfizer, Inc. · NYSE:PFE | US$156.2B | US$207.8B | 38.7× | 3.3× | 9.6× | 1.8× | 6.3% | 0.7× | 0.29 |
| Vertex Pharmaceuticals Incorporated · NASDAQ:VRTX | US$130.6B | US$128.8B | 32.8× | 9.9× | 28.4× | 6.3× | 30.7% | 0.2× | 0.47 |
| Novo Nordisk A/S Class B · OMXCOP:NOVO_B | US$129.4B | US$142.3B | 7.8× | 2.9× | 5.5× | 4.0× | 33.9% | 0.6× | n/a |
| Bristol-Myers Squibb Company · NYSE:BMY | US$120.2B | US$151.3B | 13.0× | 3.0× | n/a | 5.1× | 18.5% | 1.9× | 0.26 |
| Sanofi SA · EURONEXT:SAN | US$111.7B | US$126.9B | 14.6× | 2.3× | 4.7× | 1.4× | 13.9% | 0.3× | n/a |
| GSK plc · LSE:GSK | US$96.63B | US$123.8B | 17.0× | 2.8× | 9.3× | 3.9× | 13.0% | 1.3× | n/a |
| Median of the others | US$143.4B | US$179.5B | 26.7× | 3.3× | 9.3× | 5.1× | 15.7% | 0.6× | 0.27 |
Forecasts
Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 16329.66 GBX · Analysts' mean
- EPS, year to Dec 2026
- 10.24 · 25 analysts
- Revenue, year to Dec 2026
- 63.38B · 25 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Marc Dunoyer | Chief Executive Officer, Alexion and Chief Strategy Officer, AstraZeneca |
| Pascal Soriot | Executive Director and CEO |
| Aradhana Sarin | Executive Director and CFO |
| Jeff Pott | Chief Human Resources Officer, Chief Compliance Officer and General Counsel |
| David Fredrickson | Executive Vice-President, Oncology Business Unit |
| Iskra Reic | Executive Vice-President, International |
| Pam Cheng | Executive Vice President, Global Operations, IT & Chief Sustainability Officer |
| Ruud Dobber | Executive Vice-President, BioPharmaceuticals Business Unit |
| Sharon Barr | Executive Vice-President, BioPharmaceuticals R&D |
| Susan Galbraith | Executive Vice-President, Oncology R&D |
Board
| Director | Role |
|---|---|
| Michel Demaré | Non-Executive Chair of the Board |
| Anna Manz | Non-Executive Director |
| Aradhana Sarin | Executive Director and CFO |
| Birgit Conix | Non-Executive Director |
| Diana Layfield | Non-Executive Director |
| Euan Ashley | Non-Executive Director |
| Karen Knudsen | Non-Executive Director |
| Marcus Wallenberg | Non-Executive Director |
| Pascal Soriot | Executive Director and CEO |
| Sheri McCoy | Non-Executive Director |
| Tony Mok | Non-Executive Director |
| Wan Ling Martello | Non-Executive Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| AstraZeneca (LSE:AZN) Q2 2026 Earnings Call | Mon, Jul 27, 2026 · 6:45 AM ET | Replay |
| AstraZeneca (LSE:AZN) Q1 2026 Earnings Call | Wed, Apr 29, 2026 · 9:30 AM ET | Replay |
| AstraZeneca (LSE:AZN) Q4 2025 Earnings Call | Tue, Feb 10, 2026 · 6:45 AM ET | Replay |
| AstraZeneca (LSE:AZN) Q3 2025 Earnings Call | Tue, Nov 11, 2025 · 9:00 AM ET | Replay |
| AstraZeneca (LSE:AZN) Q2 2025 Earnings Call | Tue, Jul 29, 2025 · 9:00 AM ET | Replay |
| AstraZeneca (LSE:AZN) Q1 2025 Earnings Call | Tue, Apr 29, 2025 · 6:45 AM ET | Replay |
| AstraZeneca (LSE:AZN) Q4 2024 Earnings Call | Thu, Feb 06, 2025 · 6:00 AM ET | Replay |
| AstraZeneca (LSE:AZN) Q3 2024 Earnings Call | Tue, Nov 12, 2024 · 9:00 AM ET | Replay |
| AstraZeneca (LSE:AZN) Q2 2024 Earnings Call | Thu, Jul 25, 2024 · 6:45 AM ET | Replay |
| AstraZeneca (LSE:AZN) Q1 2024 Earnings Call | Thu, Apr 25, 2024 · 6:45 PM ET | Replay |
All 16 calls
| Call | When | Status |
|---|---|---|
| AstraZeneca (LSE:AZN) Q4 2023 Earnings Call | Thu, Feb 08, 2024 · 7:45 AM ET | Replay |
| AstraZeneca (LSE:AZN) Q3 2023 Earnings Call | Wed, Nov 15, 2023 · 9:00 AM ET | Replay |
| AstraZeneca (LSE:AZN) Q2 2023 Earnings Call | Fri, Jul 28, 2023 · 6:45 AM ET | Replay |
| AstraZeneca (LSE:AZN) Q1 2023 Earnings Call | Thu, Apr 27, 2023 · 6:45 AM ET | Replay |
| AstraZeneca (LSE:AZN) Q4 2022 Earnings Call | Thu, Feb 09, 2023 · 11:00 AM ET | Replay |
| AstraZeneca (LSE:AZN) Q2 2022 Earnings Call | Fri, Jul 29, 2022 · 6:45 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 30, 2026 · After close | −0.7% |
| Q2 2026 | Jul 27, 2026 · Before open | +1.7% |
| Q1 2026 | Apr 29, 2026 · Before open | −1.5% |
| Q4 2025 | Feb 10, 2026 · Before open | +2.0% |
| Q3 2025 | Nov 6, 2025 · Before open | +3.1% |
| Q2 2025 | Jul 29, 2025 · Before open | +3.4% |
| Q1 2025 | Apr 29, 2025 · Before open | +0.9% |
| Q4 2024 | Feb 6, 2025 · Before open | +5.9% |
| Q3 2024 | Nov 12, 2024 · Before open | +0.1% |
| Q2 2024 | Jul 25, 2024 · Before open | −1.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 25, 2024 · Before open | +5.9% |
| Q4 2023 | Feb 8, 2024 · Before open | −6.4% |
| Q3 2023 | Nov 9, 2023 · Before open | +2.6% |
| Q2 2023 | Jul 28, 2023 · Before open | +3.4% |
| Q1 2023 | Apr 27, 2023 · Before open | −0.4% |
| Q4 2022 | Feb 9, 2023 · Before open | +4.1% |
| Q3 2022 | Nov 10, 2022 · Before open | +2.9% |
| Q2 2022 | Jul 29, 2022 · Before open | −0.2% |
| Q1 2022 | Apr 29, 2022 · Before open | +1.2% |
| Quarter to Dec 31, 2021 | Feb 10, 2022 · Before open | +3.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 153 slides | Oct 30, 2026 |
| 9M and Q3 2026 Earnings Presentation | Earnings | 46 slides | Oct 30, 2026 |
| ESMO 2026 Investor Event | Conference | 59 slides | Oct 26, 2026 |
| ASBMR 2026 | Conference | 33 slides | Oct 12, 2026 |
| Meet AZN Management @ ERS 2026 | Conference | 35 slides | Sep 8, 2026 |
| H1 2026 Earnings Presentation | Earnings | 154 slides | Jul 27, 2026 |
| H1 2026 Earnings Presentation | Earnings | 43 slides | Jul 27, 2026 |
| ESG Presentation (July 2026) | Sustainability | 16 slides | Jul 6, 2026 |
| Investor Day (June 2026) | Investor day | 55 slides | Jun 8, 2026 |
| ADA 2026 | Conference | 41 slides | Jun 8, 2026 |
Show 50 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| ASCO 2026 Investor Event | Conference | 41 slides | Jun 1, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 148 slides | Apr 29, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 40 slides | Apr 29, 2026 |
| Debt Investor Presentation (February 2026) | Debt investors | 40 slides | Feb 10, 2026 |
| FY 2025 Earnings Presentation | Earnings | 163 slides | Feb 10, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 45 slides | Feb 10, 2026 |
| JP Morgan Healthcare Conference 2026 | Conference | 25 slides | Jan 13, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 39 slides | Nov 11, 2025 |
| Q3 2025 Earnings Presentation | Earnings | 156 slides | Nov 6, 2025 |
| ESMO Investor Event 2025 | Conference | 53 slides | Oct 20, 2025 |
| ESC 2025 | Conference | 33 slides | Aug 31, 2025 |
| Debt Investor Presentation (July 2025) | Debt investors | 36 slides | Jul 29, 2025 |
| H1 2025 Earnings Presentation | Earnings | 149 slides | Jul 29, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 41 slides | Jul 29, 2025 |
| ASCO Investor Event 2025 | Conference | 49 slides | Jun 2, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 143 slides | Apr 29, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 40 slides | Apr 29, 2025 |
| Debt Investor Presentation (February 2025) | Debt investors | 34 slides | Feb 6, 2025 |
| FY2024 Earnings Presentation | Earnings | 151 slides | Feb 6, 2025 |
| FY2024 Earnings Presentation | Earnings | 42 slides | Feb 6, 2025 |
| JP Morgan Healthcare Conference 2025 | Conference | 26 slides | Jan 14, 2025 |
| Investor Day (November 2024) | Investor day | 44 slides | Nov 15, 2024 |
| Q3 2024 Earnings Presentation | Earnings | 159 slides | Nov 12, 2024 |
| Q3 2024 Earnings Presentation | Earnings | 38 slides | Nov 12, 2024 |
| Investor Day (November 2024) | Investor day | 40 slides | Nov 4, 2024 |
| Investor Day (September 2024) | Investor day | 55 slides | Sep 16, 2024 |
| Investor Day (September 2024) | Investor day | 40 slides | Sep 9, 2024 |
| Debt Investor Presentation (July 2024) | Debt investors | 33 slides | Jul 25, 2024 |
| H1 2024 Earnings Presentation | Earnings | 151 slides | Jul 25, 2024 |
| H1 and Q2 2024 Earnings Presentation | Earnings | 38 slides | Jul 25, 2024 |
| Investor Day (June 2024) | Investor day | 59 slides | Jun 3, 2024 |
| Q1 2024 Earnings Presentation | Earnings | 147 slides | Apr 25, 2024 |
| Q1 2024 Earnings Presentation | Earnings | 36 slides | Apr 25, 2024 |
| ESG Presentation (March 2024) | Sustainability | 15 slides | March 2024 |
| Debt Investor Presentation (February 2024) | Debt investors | 39 slides | Feb 8, 2024 |
| FY2023 Earnings Presentation | Earnings | 144 slides | Feb 8, 2024 |
| FY2023 Earnings Presentation | Earnings | 45 slides | Feb 8, 2024 |
| JP Morgan Healthcare Conference 2024 | Conference | 26 slides | Jan 9, 2024 |
| Investor Day (2024) | Investor day | 32 slides | 2024 |
| Investor Day (2024) | Investor day | 56 slides | 2024 |
This page holds 50 of 333 decks. Open Decks
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Notes (four series) Update: €2.55B · Barclays Bank PLC +2 Dealers: Barclays Bank PLC (co-lead), Goldman Sachs International (co-lead), Morgan Stanley (co-lead) Use of proceeds: General corporate purposes | Sep 1, 2026 | US$2.98B |
| Fixed rate notes Announced: US$2B · BofA Securities, Inc. +3 Dealers: BofA Securities, Inc. (co-lead), Deutsche Bank Securities Inc. (co-lead), HSBC Securities (USA) Inc. (co-lead), Mizuho Securities USA LLC (co-lead) Use of proceeds: General corporate purposes, which may include refinancing existing indebtedness | Feb 26, 2026 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 58.7B | 54.1B | 45.8B | 44.4B | 37.4B | 26.6B | 24.4B | 22.1B | 22.5B | 23.0B |
| Cost of revenue | 10.6B | 10.2B | 8.27B | 12.4B | 12.4B | 5.30B | 4.92B | 4.94B | 4.32B | 4.13B |
| Gross profit | 48.1B | 43.9B | 37.5B | 32.0B | 25.0B | 21.3B | 19.5B | 17.2B | 18.1B | 18.9B |
| Research and development | 14.2B | 13.6B | 10.9B | 9.76B | 9.74B | 5.99B | 6.06B | 5.93B | 5.76B | 5.89B |
| Selling, general and administrative | 19.9B | 20.0B | 19.2B | 18.4B | 15.2B | 11.3B | 11.7B | 10.0B | 10.2B | 9.41B |
| Operating income | 13.7B | 10.0B | 8.19B | 3.76B | 1.06B | 5.16B | 2.92B | 3.39B | 3.68B | 4.90B |
| Depreciation and amortization | 5.73B | 5.07B | 5.39B | 5.48B | 6.53B | 3.15B | 3.76B | 2.74B | 2.47B | 2.36B |
| EBITDA | 19.5B | 15.1B | 13.6B | 9.24B | 7.59B | 8.31B | 6.69B | 6.13B | 6.14B | 7.26B |
| Interest expense | 1.69B | 1.74B | 1.63B | 1.35B | 1.30B | 1.31B | 1.43B | 1.42B | 1.51B | 1.38B |
| Income before tax | 12.4B | 8.69B | 6.90B | 2.50B | -265.0M | 3.92B | 1.55B | 1.99B | 2.23B | 3.55B |
| Income tax | 2.17B | 1.65B | 938.0M | -792.0M | -380.0M | 772.0M | 321.0M | -57.0M | -641.0M | 146.0M |
| Net income | 10.2B | 7.04B | 5.96B | 3.29B | 112.0M | 3.20B | 1.33B | 2.15B | 3.00B | 3.50B |
| Earnings per share, basic | 6.60 | 4.54 | 3.84 | 2.12 | 0.08 | 2.44 | 1.03 | 1.70 | 2.37 | 2.77 |
| Earnings per share, diluted | 6.54 | 4.50 | 3.81 | 2.11 | 0.08 | 2.44 | 1.03 | 1.70 | 2.37 | 2.76 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 5.71B | 5.49B | 5.84B | 6.17B | 6.33B | 7.83B | 5.37B | 4.83B | 3.32B | 5.02B |
| Short-term investments | 30.0M | 166.0M | 122.0M | 239.0M | 69.0M | 160.0M | 849.0M | 849.0M | 1.23B | 884.0M |
| Receivables | 15.2B | 13.0B | 12.1B | 10.5B | 9.64B | 7.02B | 5.76B | 5.57B | 5.01B | 4.57B |
| Inventory | 6.56B | 5.29B | 5.42B | 4.70B | 8.98B | 4.02B | 3.19B | 2.89B | 3.04B | 2.33B |
| Current assets | 28.7B | 25.8B | 25.1B | 22.6B | 26.2B | 19.5B | 15.6B | 15.6B | 13.2B | 13.3B |
| Property, plant and equipment | 13.0B | 10.3B | 9.40B | 8.51B | 9.18B | 8.25B | 7.69B | 7.42B | 7.62B | 6.85B |
| Goodwill | 21.2B | 21.0B | 20.0B | 19.8B | 20.0B | 11.8B | 11.7B | 11.7B | 11.8B | 11.7B |
| Total assets | 114.1B | 104.0B | 101.1B | 96.5B | 105.4B | 66.7B | 61.4B | 60.7B | 63.4B | 62.5B |
| Accounts payable | 25.3B | 22.5B | 22.4B | 19.0B | 18.9B | 15.8B | 14.0B | 12.8B | 11.6B | 10.5B |
| Current liabilities | 30.6B | 27.9B | 30.5B | 26.3B | 22.6B | 20.3B | 18.1B | 16.3B | 16.4B | 15.3B |
| Long-term debt | 24.7B | 26.5B | 22.4B | 23.0B | 28.1B | 17.5B | 15.7B | 17.4B | 15.6B | 14.5B |
| Total debt | 29.6B | 30.3B | 28.6B | 29.2B | 30.8B | 20.4B | 18.2B | 19.1B | 17.8B | 16.8B |
| Total liabilities | 65.4B | 63.2B | 62.0B | 59.4B | 66.1B | 51.1B | 46.8B | 46.6B | 46.7B | 45.9B |
| Shareholders' equity | 48.7B | 40.8B | 39.1B | 37.0B | 39.3B | 15.6B | 13.1B | 12.5B | 15.0B | 14.9B |
| Shares outstanding | 1.56B | 1.56B | 1.56B | 1.56B | 1.43B | 1.31B | 1.30B | 1.27B | 1.27B | 1.27B |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 14.6B | 11.9B | 10.3B | 9.81B | 5.96B | 4.80B | 2.97B | 2.62B | 3.58B | 4.14B |
| Capital spending | -2.81B | -1.92B | -1.36B | -1.09B | -1.09B | -961.0M | -979.0M | -1.04B | -1.33B | -1.45B |
| Free cash flow | 11.8B | 9.94B | 8.98B | 8.72B | 4.87B | 3.84B | 1.99B | 1.57B | 2.25B | 2.70B |
| Cash from investing | -6.81B | -7.98B | -4.06B | -2.96B | -11.1B | -285.0M | -657.0M | 963.0M | -2.33B | -3.97B |
| Cash from financing | -7.54B | -4.00B | -6.57B | -6.82B | 3.65B | -2.20B | -1.76B | -2.04B | -2.94B | -1.32B |
| Dividends paid | -4.97B | -4.63B | -4.48B | -4.36B | -3.86B | -3.57B | -3.59B | -3.48B | -3.52B | -3.56B |
| Share buybacks | -521.0M | -81.0M | 3.71B | -920.0M | -149.0M | 3.05B | 314.0M | 2.97B | 2.31B | 2.78B |
| Change in cash | 223.0M | -115.0M | -286.0M | 25.0M | -1.45B | 2.31B | 547.0M | 1.54B | -1.69B | -1.15B |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 16, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 16, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 16, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 16, 2026 | Current report | SEC |
| 4 · Change in ownership | Nov 10, 2026 | Insider trade | SEC |
| 6-K · Report of a foreign issuer | Nov 2, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 2, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 30, 2026 | Current report | SEC |
| 3rd Quarter Results | Oct 30, 2026 | Other filings | London Stock Exchange |
| 6-K · Report of a foreign issuer | Oct 27, 2026 | Current report | SEC |
Show 200 filings
This page holds 200 of 1,003 filings. Open Filings
Cap table
Built by 6ix from AstraZeneca PLC’s releases · as of Feb 26, 2026
- Common shares
- 1,550,917,690
- Fully diluted
- 1,550,917,690
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,550,917,690 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,550,917,690 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Euan Ashley Other companies: DexCom, Inc. (Director · Since at least Oct 24, 2025) | Non-Executive Director · Since at least Nov 5, 2026 |
| Anna Manz | Non-Executive Director · Since at least Nov 5, 2026 |
| Aradhana Sarin | Executive Director and CFO · Since at least Nov 5, 2026 |
| Birgit Conix | Non-Executive Director · Since at least Nov 5, 2026 |
| David Fredrickson | Executive Vice-President, Oncology Business Unit · Since at least Nov 4, 2026 |
| Diana Layfield | Non-Executive Director · Since at least Nov 5, 2026 |
| Iskra Reic | Executive Vice-President, International · Since at least Jul 27, 2026 |
| Jeff Pott | Chief Human Resources Officer, Chief Compliance Officer and General Counsel · Since at least Nov 4, 2026 |
| Karen Knudsen | Non-Executive Director · Since at least Nov 5, 2026 |
| Mani Sharma | See remarks · Since at least Mar 18, 2026 |
All 22 people
| Person | Seat |
|---|---|
| Marc Dunoyer | Chief Executive Officer, Alexion and Chief Strategy Officer, AstraZeneca · Since at least Oct 22, 2026 |
| Marcus Wallenberg | Non-Executive Director · Since at least Nov 5, 2026 |
| Maria Belvisi | Chief Scientific Officer · Apr 10, 2026 – Nov 5, 2026 · Past |
| Michel Demaré | Non-Executive Chair of the Board · Since at least Jul 27, 2026 |
| Pam Cheng | Executive Vice President, Global Operations, IT & Chief Sustainability Officer · Since at least Oct 30, 2026 |
| Pascal Soriot | Executive Director and CEO · Since at least Oct 30, 2026 |
| Ruud Dobber | Executive Vice-President, BioPharmaceuticals Business Unit · Since at least Sep 23, 2026 |
| Sharon Barr | Executive Vice-President, BioPharmaceuticals R&D · Since at least Sep 8, 2026 |
| Sheri McCoy | Non-Executive Director · Since at least Nov 5, 2026 |
| Susan Galbraith | Executive Vice-President, Oncology R&D · Since at least Oct 25, 2026 |
| Tony Mok | Non-Executive Director · Since at least Nov 4, 2026 |
| Wan Ling Martello | Non-Executive Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about AstraZeneca PLC.